Centiva Capital LP Acquires 4,246 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Centiva Capital LP grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 58.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,511 shares of the medical research company's stock after acquiring an additional 4,246 shares during the quarter. Centiva Capital LP's holdings in Charles River Laboratories International were worth $2,125,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in CRL. Brevan Howard Capital Management LP grew its position in Charles River Laboratories International by 90.0% in the 4th quarter. Brevan Howard Capital Management LP now owns 8,008 shares of the medical research company's stock worth $1,478,000 after purchasing an additional 3,794 shares during the period. Bridgefront Capital LLC grew its holdings in shares of Charles River Laboratories International by 52.6% in the fourth quarter. Bridgefront Capital LLC now owns 5,845 shares of the medical research company's stock worth $1,079,000 after acquiring an additional 2,014 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Charles River Laboratories International during the fourth quarter valued at $1,052,000. Bayesian Capital Management LP bought a new position in Charles River Laboratories International in the fourth quarter valued at about $3,316,000. Finally, BNP Paribas Financial Markets lifted its holdings in Charles River Laboratories International by 13.8% in the fourth quarter. BNP Paribas Financial Markets now owns 90,083 shares of the medical research company's stock valued at $16,629,000 after acquiring an additional 10,912 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded down $2.52 during mid-day trading on Friday, reaching $138.84. The stock had a trading volume of 920,260 shares, compared to its average volume of 966,135. The company has a market cap of $6.82 billion, a P/E ratio of 925.60, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The business's 50 day moving average price is $138.40 and its 200 day moving average price is $166.46. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. During the same quarter in the previous year, the business posted $2.27 earnings per share. Charles River Laboratories International's quarterly revenue was down 2.7% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company's stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on CRL. Mizuho reduced their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target on the stock in a research report on Thursday. Barclays boosted their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Finally, UBS Group restated a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $176.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).